Loading…
← CockpitCompetitor Analysis › 600165.SS Ningxia Zhongke Biotechnology Co., Ltd. Class AOpen in the cockpit ↗

Ningxia Zhongke Biotechnology Co., Ltd. Class A600165.SSCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Major Diversified
Momentum strong 72
Mkt cap
$601M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$5.35M
20-day average traded
P/B
3.94×
price to book
ROE
-7.3%
delivered
Implied ROE
24.2%
what the price asks
Close · CNYCN¥2.52
1D+2.4%
1W-7.7%
1M-16.8%
3M0.0%
6M-17.1%
YTD-39.3%
1Y-32.1%
ATR %5.0%
52w lowhigh43.2% off high

What Ningxia Zhongke Biotechnology does

Employees: 904

Ningxia Zhongke Biotechnology at a glance

Size Ningxia Zhongke Biotechnology (600165.SS) is a China Materials company (Chemicals: Major Diversified) with a market value of $601M, the 3239th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.52 on 18 Nov 2026.

Performance Over six months the shares fell 17.1%, against -23.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 8.2% over the last twelve months (peer median +6.3%); the operating margin is -73.1% (peer median 6.0%).

Valuation It trades at 3.94× book value against a peer median of 2.12× (6th most expensive of 21).

Price implies The share price implies a return on equity of about 24.2%; Ningxia Zhongke Biotechnology delivers -7.3%, so the price asks more than the business earns today.

Relative performance

8010021 May 202621 Aug 202618 Nov 2026600165.SS 85Peer median 75
Six months, rebased to 100: Ningxia Zhongke Biotechnology against the median of its 20 peers (local-currency closes).

Ningxia Zhongke Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥528MCN¥444MCN¥344MCN¥285MCN¥681M
Revenue growth—+29%+21%-58%—
Gross profit-CN¥50.8M-CN¥107M-CN¥79.7M-CN¥111MCN¥64.2M
EBITDA-CN¥260M-CN¥197M-CN¥81.4M-CN¥65.5MCN¥36.4M
Net income-CN¥30.4M-CN¥90.4M-CN¥539M-CN¥466M-CN¥141M
Free cash flow-CN¥702M-CN¥645M-CN¥91.4M-CN¥34.5MCN¥7.95M
Capital expenditureCN¥288MCN¥271MCN¥6.20MCN¥57.7MCN¥59.3M
Total debtCN¥16.4MCN¥860MCN¥677MCN¥1.69BCN¥1.65B

Quarterly statements and history in the cockpit →

Ningxia Zhongke Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%603285688750603004300801ACI3005373012060006356033510022743000823008396882676886690027833005306882373001215234300055600165.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Ningxia Zhongke Biotechnology is the large dot.

Fundamentals: return on equity against price-to-book

-60%-40%-20%0%20×40×60×603285688750603004300801ACI3005373012060006350022743008396886693005306882375234300055600165.SSReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Ningxia Zhongke Biotechnology is the large dot.

Capital: ROE delivered against the ROE the price implies

-50%-25%0%25%50%-50%0%50%603285688750603004300801ACI3005373012060006356886693005305234600165.SSROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Ningxia Zhongke Biotechnology is the large dot.

Ningxia Zhongke Biotechnology competitors and peer comparison

How Ningxia Zhongke Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ningxia Zhongke Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure600165.SSPeer medianRank in peer set
1-month return-16.8%-9.9%4th lowest of 21
6-month return-17.1%-23.6%7th highest of 21
Return on equity-7.3%3.9%4th lowest of 21
Price / book3.94×2.12×6th most expensive of 21
ROE the price implies24.2%19.9%8th most demanding of 21
ROE delivered-7.3%3.9%4th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Ningxia Zhongke Biotechnology 600165.SSChina$601M-17%+8%-7%3.94×24.2%-7.3%
Shandong Jianbang New Material 603285.SSChina$594M-50%+8%8%2.25×23.6%7.9%
Hunan Xiangtou Goldsky Titanium Industry Technology 688750.SSChina$585M-29%+4%4%2.32×28.1%3.6%
Zhejiang Dragon Technology 603004.SSChina$582M-22%-11%5%1.84×19.1%4.8%
Shandong Taihe Technologies 300801.SZChina$582M-42%-2%5%1.44×15.3%5.2%
Archean Chemical Industries ACI.NSIndia$576M-19%+6%5%2.74×20.7%5.2%
Jiangsu Kuangshun Photosensitivity New Material Stock 300537.SZChina$568M-33%+15%3%4.12×42.1%3.2%
Shandong Sanyuan Biotechnology 301206.SZChina$644M-21%+15%2%1.02×8.2%1.8%
Ningxia Yinglite Chemicals 000635.SZChina$650M+35%-14%-62%5.37×38.3%-62.2%
Nanjing Well Pharmaceutical 603351.SSChina$550M-2%+7%9%2.00×13.8%8.7%
Jiansu Huachang Chemical 002274.SZChina$663M-25%+9%-3%0.85×7.4%-3.3%
Liaoning Oxiranchem,Inc 300082.SZChina$673M-45%+4%4%1.59×16.8%3.8%
Ningbo Bohui Chemical Technology 300839.SZChina$533M-35%+42%8%4.34×29.0%8.5%
China Catalyst 688267.SSChina$532M-38%-3%5%1.24×9.7%4.8%
Polyrocks Chemical 688669.SSChina$529M-16%-8%-27%3.53×43.1%-27.2%
Hubei Kailong Chemical 002783.SZChina$528M-18%-2%4%1.29×9.0%4.0%
Hunan Lead Power Technology 300530.SZChina$691M+12%+16%-58%60.81×506.5%-57.5%
Hubei Chaozhuo Aviation Technology 688237.SSChina$697M-5%-1%1%3.83×22.8%1.0%
Shandong Yanggu Huatai Chemical 300121.SZChina$703M-16%+11%4%1.27×12.4%4.4%
Daxin Materials 5234.TWTaiwan$705M-39%+12%26%6.54×57.7%26.2%
Beijing WBD New Materials 300055.SZChina$512M-56%+13%-5%0.82×7.6%-5.0%

Questions

Which companies are Ningxia Zhongke Biotechnology's closest peers?
The cockpit's peer set: Shandong Jianbang New Material (603285.SS), Hunan Xiangtou Goldsky Titanium Industry Technology (688750.SS), Zhejiang Dragon Technology (603004.SS), Shandong Taihe Technologies (300801.SZ), Archean Chemical Industries (ACI.NS), Jiangsu Kuangshun Photosensitivity New Material Stock (300537.SZ), Shandong Sanyuan Biotechnology (301206.SZ), Ningxia Yinglite Chemicals (000635.SZ).
Is Ningxia Zhongke Biotechnology expensive compared with its peers?
On price / book it trades at 3.94× against a peer median of 2.12×, 6th most expensive of 21 in its peer set. The share price implies a return on equity of about 24.2%; Ningxia Zhongke Biotechnology delivers -7.3%, so the price asks more than the business earns today.
How has Ningxia Zhongke Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -17.1% against -23.6% for the median peer; over one year -32.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.